Different of economic analyses are sometimes delivered to compare different health procedures. In this chapter we apply a cost-effectiveness analysis to a validated Group Care approach for diabetic patients, as compared with traditional, individually delivered care and education. Working on a differential basis, differential (and greater) costs associated with Group Care are opposed to its differential (and better) outcomes. Costs comprise differential direct costs, either paid by the Italian National Health System (mainly staff costs) or by patients (transportation and opportunity costs of time allocated to the two procedures). As the main endpoint in either case (a 4-year follow-up for type 2 with 90 patients, and a 3-year follow-up for type 1, with 62 patients, in both cases randomly assigned to the two competing procedures), we chose differrential scores in perceived quality of life, which proved meaningful and statistically robust. Resulting cost-effectiveness ratios are EUR 2.28 per point in the DQOL score for type 2 diabetes, and EUR 19.46 for patients with type 1. This was in both cases a very reasonable additional burden that – from a societal point of view – makes future extensions of Group Care very attractive. The robustedness of the results are discussed and tested in sensitivity analyses, run by changing the end-points and/or cost composition.

A cost-effectiveness analysis of group care in type 2 and type 1 diabetes

BONDONIO, Piervincenzo;TRENTO, Marina;PORTA, Massimo
2005

Abstract

Different of economic analyses are sometimes delivered to compare different health procedures. In this chapter we apply a cost-effectiveness analysis to a validated Group Care approach for diabetic patients, as compared with traditional, individually delivered care and education. Working on a differential basis, differential (and greater) costs associated with Group Care are opposed to its differential (and better) outcomes. Costs comprise differential direct costs, either paid by the Italian National Health System (mainly staff costs) or by patients (transportation and opportunity costs of time allocated to the two procedures). As the main endpoint in either case (a 4-year follow-up for type 2 with 90 patients, and a 3-year follow-up for type 1, with 62 patients, in both cases randomly assigned to the two competing procedures), we chose differrential scores in perceived quality of life, which proved meaningful and statistically robust. Resulting cost-effectiveness ratios are EUR 2.28 per point in the DQOL score for type 2 diabetes, and EUR 19.46 for patients with type 1. This was in both cases a very reasonable additional burden that – from a societal point of view – makes future extensions of Group Care very attractive. The robustedness of the results are discussed and tested in sensitivity analyses, run by changing the end-points and/or cost composition.
Embedding education into diabetes practice
Karger
uno
117
131
9783805579612
cost effectiveness analysis; group care; diabetes type 1 and type 2
P. BONDONIO; M. TRENTO; M. PORTA
File in questo prodotto:
File Dimensione Formato  
costi.PDF

non disponibili

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 597.51 kB
Formato Adobe PDF
597.51 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/104622
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact